SenzaGen AB continues to gear up its operations
2014-11-12, Lund, Sweden
SenzaGen AB, a diagnostic spin-off company from Lund University, announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board of directors.
SenzaGen AB, a diagnostic company working to replace animal testing, recently announced the recruitment of Dr. Anki Malmborg Hager as CEO. The company now continues to recruit top level associates and hereby announces that Dr Carl-Henric Nilsson and Ann Gidner will join the board.
SenzaGen AB is based on research at the Department of Immunotechnology at Lund University, providing animal-free, in vitro sensitization tests for the cosmetic, chemical, pharmaceutical and food industries.
“We are entering into a very exciting commercial phase and are happy to be able to engage board members with international experience from our target markets,” says Prof. Carl Borrebaeck, chairman of the board of SenzaGen.
Carl-Henric Nilsson holds a PhD and M.Sc. in Industrial management, and is Associate Professor at Lund University, School of Economics and Management. He is CEO of Kunskapspartner AB, Chairman of Kunskapspartner Holding AB, Boardmember in FX International AB and Boffins Holding AB. Carl-Henric’s research is focused on Business development and Industrialization with numerous scientific publications. Carl-Henric is working with entrepreneurs on a global basis with a broad contact net, especially in China and the United States.
Ann Gidner holds a Master of Science in Chemical Engineering /Bioprocessing and a Bachelor in Business Administration. She has extensive international experience from the chemical industry with global leading positions in e.g. Cambrex and Lanxess Corporations. Furthermore, she has held managing positions in RFR Solutions AB, Semcon Caran AB, and Monocl AB. She is currently Director of Sales & Business Development Europe at Novozymes Biopharma, Copenhagen.
Other members of the board are chairman Carl Borrebaeck and deputy Malin Lindstedt.
About SenzaGen
SenzaGen AB is an early-phase diagnostics company based on strong research and know-how of the immune system and its reaction to hazardous agents, such as irritants and allergens. The company’s products are genetic tests for sensitizing agents, which have been designed based on how indicator cells react when exposed to a variety of chemicals.
SenzaGen AB was created to meet the international demand to replace existing animal testing for regulatory purposes and to provide novel tools for early decision-making in product development. SenzaGen AB services will offer the most accurate, animal-free in vitro testing option for manufacturers of cosmetics, chemicals, food, and pharmaceuticals.
SenzaGen AB is a spin-off company founded by researchers at Lund University to bring academic results to good use for society. The company is situated in facilities at Medicon Village, Lund, Sweden.
For more information please contact:
Carl Borrebaeck, Chairman of the Board, SenzaGen AB
+46 708 218330